Seasonal Influenza Market Anticipated To Witness Robust Growth, Surpassing 18.54 Billion By 2029

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Seasonal Influenza Market Size and Its Estimated Growth Rate?
The market size of seasonal influenza has witnessed a rapid expansion in the recent past. It is set to swell from $8.41 billion in 2024 to a whopping $9.88 billion in 2025 with a compound annual growth rate (CAGR) hitting 17.4%. Factors contributing to this growth during the historic period include an increase in influenza incidence, growth of the aged population, a surge in the occurrence of infectious and chronic ailments, heightened affliction of influenza-related diseases, and an escalation in respiratory infections.

The market for seasonal influenza is anticipated to experience rapid expansion in the upcoming years, with a projected value of $18.55 billion in 2029, representing a compound annual growth rate (CAGR) of 17.1%. This growth during the projection period can be ascribed to a rise in demand for orally administered medication, expansion in research and development activities, increased vaccination rates, enhancements in healthcare facilities, and a growing need for retail pharmacies. Future trends in the market may encompass advancements in treatments and technologies, vaccine technology innovation, mRNA technology implementation, and the development of digital health solutions for tracking and diagnosis.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21285

How Are Emerging Segments Shaping the Seasonal Influenza Market Landscape?
The seasonal influenza market covered in this report is segmented -

1) By Type: Influenza A Virus, Influenza B Virus, Influenza C Virus, Influenza D Virus
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital, Government and institutional supply, Pharmacy, Online
4) By Treatment: Antiviral, Neuraminidase Inhibitors, Vaccination, Other Treatments

Subsegments:
1) By Influenza A Virus: Subtype H1N1, Subtype H3N2, Other Subtypes
2) By Influenza B Virus: Lineage Victoria, Lineage Yamagata
3) By Influenza C Virus: Seasonal C Virus, Non-seasonal C Virus
4) By Influenza D Virus: Animal-associated Influenza D

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21285&type=smp

Which Growth Factors Are Influencing Seasonal Influenza Market Expansion?
The escalating occurrence of respiratory illnesses is anticipated to boost the expansion of the seasonal influenza market in the near future. These respiratory conditions, which can affect the sinuses, throat, airways, or lungs, are the result of bacteria or viruses. The rising incidence is attributed to factors such as air pollution, changing weather patterns, weakened immune system, and the facility of viral spread in overcrowded or poorly ventilated places. Treatments for seasonal influenza contribute to the deterrence or curtailment of respiratory ailments in multiple ways, specifically through addressing the influenza virus and managing symptoms that could lead to additional infections. To illustrate, in October 2024, the UK Health Security Agency, a government institution based in the UK, reported a 10.7% annual increase in 2023, in the number of tuberculosis (TB) cases in England, caused by the bacterium Mycobacterium tuberculosis, a type of respiratory infection. This rose from 4,380 cases in 2022 to 4,850 cases. Thus, the upsurge in respiratory infections will steer the growth of the seasonal influenza market.

Who Are the Dominant Players Across Different Seasonal Influenza Market Segments?
Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

What Are the Major Trends Shaping the Seasonal Influenza Market?
Leading corporations in the seasonal influenza marketplace are prioritizing advancements in treatments, such as combination vaccines, in an aim to amplify immunity by addressing various strains of the virus and improving efficiency while decreasing the need for consistent vaccinations. Combination vaccines offer protection against an array of diseases or strains in just one injection, cutting down the need for multiple shots for immunization. For instance, Moderna, Inc., a biotechnology firm based in the United States, reported positive preliminary Phase 1/2 trial outcomes for mRNA-1083, their under-investigation combination vaccine for both influenza and COVID-19, in October 2023. mRNA-1083 is aimed at enhancing compliance, simplifying administration, and increasing convenience for individuals and healthcare systems alike. It is currently under review for safety and immunogenicity in standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), and is also being compared with the Spikevax booster.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/seasonal-influenza-global-market-report

Which Geographic Regions Are Expected to Dominate the Seasonal Influenza Market in the Coming Years?
North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seasonal influenza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Seasonal Influenza Market?
2. What is the CAGR expected in the Seasonal Influenza Market?
3. What Are the Key Innovations Transforming the Seasonal Influenza Industry?
4. Which Region Is Leading the Seasonal Influenza Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.